市場今すぐ寄付してください会員になる

カート (0)

DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか？ or パスワードをお忘れですか？

Not a Member?

アカウントを作成して参加。

世界的なイベント

Hyatt Regency Bethesda

2015年4月13日 (月) 午前 7:00 - 2015年4月15日 (水) 午後 12:00

One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814-5326

CMC Workshop 2015

戻る Agendas

Session 9C: Clinically Relevant Specifications: Technical Considerations and Regulatory Expectations

Session Chair(s)

Nagesh Bandi, PHD

Nagesh Bandi, PHD

Executive Director, Merck & Co., Inc, United States

Due to the critical role that dissolution plays in the bioavailability of a drug, in vitro dissolution can serve as a relevant predictor of the in vivo performance of the drug product. There is growing evidence that clinically meaningful dissolution specifications will minimize variability to the patient and therefore will optimize drug therapy. This session will discuss the relevant CMC and clinical pharmacology-related factors that should be considered in developing a clinically relevant dissolution method and specifications. In addition, the regulatory expectations and considerations will be illustrated.

Speaker(s)

Philip Floyd, PHD

Global Vice President, Analytical R&D, AbbVie, United States

Novel Approaches to Better Understand Drug Product Design and Testing

Vivek Purohit, PHD

Director, Pfizer, Inc., US, United States

Strategies for Ensuring Dissolution and Clinical Performance

Angelica Dorantes, PHD, MSC

Biopharmaceutics Branch Chief (acting), Office of Pharmaceutical Quality, CDER, FDA, United States

Clinically Relevant Specifications: FDA Perspective